Free RAC-GS Exam Braindumps (page: 8)

Page 8 of 26

According to ICH, what is the MAXIMUM amount of timein calendar days that anorganizationhas from the initial receipt of information to report serious and unexpected ADR of a marketed product to regulatory authorities?

  1. 3
  2. 5
  3. 10
  4. 15

Answer(s): B,C,D



One month prior to the anticipated approval date for your product, the marketing application that you submitted to a major regulatory authority has become the subject of an advisory committee meeting of experts convened by the regulatory authority. The advisory committee members unanimously vote not to approve your product because of a safety concern. Two days after the advisory committee meeting, the regulatory authority requests additional information to support the safety of your product. Assuming you have no additional data to provide, which of the following would be your MOST appropriate response to the regulatory authority's request?

  1. "Given the advisory committee's unanimous decision, we know that the product will not be approved, and additional data will not make any difference."
  2. "We have no additional informationto provide at this time, but wecan perform an additional analysis for a specific safety concern, if necessary."
  3. "We disagree with the advisory committee's decision because the committee neglected the thorough safety analysis that we provided."
  4. "We have no additional information to provide at this time because we have already provided everything needed to support our product's approval."

Answer(s): B



At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?

  1. Quality improvement
  2. Quality assurance
  3. Clinical affairs
  4. Regulatory agency

Answer(s): B



In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?

  1. Potential clinical sites for the Phase III clinical trial
  2. Regulatory requirements for labeling and packaging
  3. Capacity of the manufacturing facilities to fully produce the new product
  4. Previous actions taken by regulatory authorities on similar products

Answer(s): D



Page 8 of 26



Post your Comments and Discuss RAPS RAC-GS exam with other Community members:

Raymond commented on May 02, 2022
Best way to cheat your exam. hahaha... all questions are in this dexam dump.
UNITED STATES
upvote